Boston Partners Increases Stock Holdings in Chemed Corporation $CHE

Boston Partners increased its position in shares of Chemed Corporation (NYSE:CHE) by 37.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 22,651 shares of the company’s stock after acquiring an additional 6,125 shares during the period. Boston Partners’ holdings in Chemed were worth $11,028,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the company. Allworth Financial LP grew its position in Chemed by 20.5% during the second quarter. Allworth Financial LP now owns 188 shares of the company’s stock worth $92,000 after buying an additional 32 shares in the last quarter. Illinois Municipal Retirement Fund lifted its holdings in shares of Chemed by 54.4% during the 2nd quarter. Illinois Municipal Retirement Fund now owns 7,929 shares of the company’s stock worth $3,861,000 after acquiring an additional 2,792 shares during the last quarter. ProShare Advisors LLC grew its position in Chemed by 1.4% in the second quarter. ProShare Advisors LLC now owns 56,504 shares of the company’s stock worth $27,513,000 after acquiring an additional 779 shares in the last quarter. Acadian Asset Management LLC increased its stake in Chemed by 69.3% in the second quarter. Acadian Asset Management LLC now owns 250,722 shares of the company’s stock valued at $122,056,000 after acquiring an additional 102,597 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Chemed during the second quarter valued at about $2,992,000. Institutional investors own 95.85% of the company’s stock.

Analysts Set New Price Targets

CHE has been the subject of a number of research reports. Royal Bank Of Canada cut their price objective on Chemed from $589.00 to $572.00 and set an “outperform” rating for the company in a report on Monday. Bank of America dropped their target price on Chemed from $610.00 to $595.00 and set a “buy” rating for the company in a research report on Wednesday, September 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Chemed in a research report on Wednesday, October 8th. Oppenheimer lowered their price objective on shares of Chemed from $650.00 to $580.00 and set an “outperform” rating for the company in a report on Thursday, July 31st. Finally, Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 30th. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $574.25.

Insider Transactions at Chemed

In other news, Director Patrick P. Grace sold 150 shares of Chemed stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $463.39, for a total value of $69,508.50. Following the sale, the director directly owned 3,397 shares in the company, valued at approximately $1,574,135.83. This trade represents a 4.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kevin J. Mcnamara sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $461.28, for a total value of $1,383,840.00. Following the transaction, the chief executive officer directly owned 96,197 shares in the company, valued at $44,373,752.16. This trade represents a 3.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 3.29% of the stock is owned by insiders.

Chemed Stock Performance

Shares of Chemed stock opened at $445.87 on Friday. Chemed Corporation has a 52-week low of $408.42 and a 52-week high of $623.60. The company’s 50 day moving average price is $444.58 and its 200-day moving average price is $485.06. The stock has a market capitalization of $6.32 billion, a price-to-earnings ratio of 23.58, a P/E/G ratio of 2.69 and a beta of 0.43.

Chemed (NYSE:CHE) last posted its quarterly earnings results on Tuesday, October 28th. The company reported $5.27 EPS for the quarter, missing analysts’ consensus estimates of $5.39 by ($0.12). The firm had revenue of $624.90 million for the quarter, compared to the consensus estimate of $626.04 million. Chemed had a net margin of 11.02% and a return on equity of 25.89%. The company’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $5.64 earnings per share. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, equities research analysts forecast that Chemed Corporation will post 21.43 earnings per share for the current fiscal year.

Chemed Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Monday, November 17th will be paid a $0.60 dividend. The ex-dividend date of this dividend is Monday, November 17th. This represents a $2.40 annualized dividend and a dividend yield of 0.5%. Chemed’s dividend payout ratio (DPR) is presently 12.69%.

Chemed Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.